

Article

1  
2 Classification: BIOLOGICAL SCIENCES – Medical Sciences

3 **Protein nitration is a physiological regulator of cardiac lactate dehydrogenase active**  
4 **site loop mobility and activity**

5 Cristian Nogales<sup>a,1,\*</sup>, Jeroen Frijhoff<sup>b,1</sup>, Detlef Thoenges<sup>c</sup>, Richard B. Sessions<sup>d</sup>, Albert  
6 Sickmann<sup>e</sup>, Tatiana Nedvetskaya<sup>f</sup>, Cesar Ibarra-Alvarado<sup>g</sup>, Vera Schmitz<sup>h</sup>, Peter Rösen<sup>h</sup>,  
7 Axel Goedecke<sup>i</sup>, Aleksandar Jovanović<sup>j</sup>, David H. Perlman<sup>k</sup>, Anna Klinke<sup>l</sup>, Stephan Baldus<sup>l</sup>,  
8 Ana I. Casas<sup>a</sup>, Péter Bai<sup>m</sup>, Csaba Szabo<sup>n</sup>, Martin Feelisch<sup>o</sup>, Harald H.H.W. Schmidt<sup>a,\*</sup>.

9 <sup>a</sup>Department of Pharmacology and Personalised Medicine, Maastricht University,  
10 Maastricht, The Netherlands; <sup>b</sup>Medtronic Bakken Research Center, Maastricht, The  
11 Netherlands; <sup>c</sup>DiaSys Diagnostic Systems GmbH, Holzheim, Germany; <sup>d</sup>School of  
12 Biochemistry, University of Bristol, Bristol, UK; <sup>e</sup>Leibniz-Institut für Analytische  
13 Wissenschaften – ISAS, Dortmund, Germany; <sup>f</sup>Rudolf-Buchheim-Institut für Pharmakologie,  
14 Justus-Liebig-University, Giessen, Germany; <sup>g</sup>School of Chemistry, Autonomous University  
15 of Querétaro, Querétaro, México; <sup>h</sup>German Diabetes Research Institute, Düsseldorf,  
16 Germany; <sup>i</sup>Heinrich-Heine-University, Department Cardiovascular Physiology, Düsseldorf,  
17 Germany; <sup>j</sup>University of Nicosia Medical School, Nicosia, Cyprus; <sup>k</sup>Merck Exploratory  
18 Science Center, Cambridge, Massachusetts; <sup>l</sup>Cologne Cardiovascular Research Center  
19 CCRC, Cologne, Germany; <sup>m</sup>Department of Medical Chemistry, Faculty of Medicine,  
20 University of Debrecen, Debrecen, Hungary and MTA-DE Lendület Laboratory of Cellular  
21 Metabolism, Debrecen, Hungary; <sup>n</sup>Department of Oncology, Microbiology and Immunology;  
22 University of Fribourg, Fribourg, Switzerland; <sup>o</sup>University of Southampton Medical School,  
23 Southampton, UK.

24 <sup>1</sup>Both first authors contributed equally to this work.

25 <sup>\*</sup>To whom correspondence may be addressed. Email: [h.schmidt@maastrichtuniversity.nl](mailto:h.schmidt@maastrichtuniversity.nl) or  
26 [c.nogales@maastrichtuniversity.nl](mailto:c.nogales@maastrichtuniversity.nl)

1

2 **Key words:** protein nitration, nitro-tryptophan, nitro-tyrosine, biomarker

3 **Word count (main text including references):** 24578 characters (including spaces)

## 1 **Abstract**

2 Protein tyrosine nitration, detected as anti-nitrotyrosine immunoreactivity, is considered one  
3 of the most relevant disease biomarkers of oxidative stress. The mechanism of nitration,  
4 target protein and functional consequences remain often unclear. Here we first extend  
5 protein tyrosine nitration from pathology to physiology as additional mechanism of post-  
6 translational regulation. We focus on a prominent protein band surprisingly nitrotyrosine  
7 immunopositive under basal conditions in mouse, rat and pig heart and more so in diabetes  
8 and myocardial stress. Upon purification, we identify it as lactate dehydrogenase (LDH) and  
9 its basal nitration depending on NO synthase (NOS) and myeloperoxidase (MPO),  
10 respectively. Surprisingly, we locate LDH nitration by MALDI-TOF mass spectrometry not to  
11 a tyrosine but the C-terminal tryptophan, Trp-324. Molecular dynamics simulations  
12 suggested that Trp-324 nitration restricts the interaction of the active site loop with the C-  
13 terminal  $\alpha$ -helix essential for activity, which was corroborated by an apparent lower  $V_{max}$ . In  
14 summary, protein nitration is not merely a disease marker but also a physiological event  
15 involving both the eNOS/NO and the MPO/nitrite pathways. In the case of LDH, to our  
16 knowledge the first protein identified to be basally regulated by nitration, this limits its activity,  
17 which is aggravated under cardiac metabolic stress conditions.

## 1 **Significance**

2 Protein nitration is the most widely used disease marker indicating oxidative stress. How  
3 nitration occurs and its functional consequences have remained unclear in many cases.  
4 Here we show that protein nitration is not limited to disease but also occurs physiologically.  
5 We identify a key enzyme of energy metabolism in the heart as a target of nitration and two  
6 mechanisms equally responsible for its formation resulting in lower activity. Thus, protein  
7 nitration does not necessarily indicate a disease process but a physiological protein  
8 modification, e.g. for dynamic regulation of enzymatic activity.

1 **\body**

2 **Introduction**

3 Increased levels of reactive oxygen species (ROS), i.e. oxidative stress, is considered a  
4 common mechanism of several cardiovascular and other disease states (1). In concert with  
5 different nitrogen species (2–4), ROS can lead to protein nitration, e.g. tyrosine residues  
6 (NO<sub>2</sub>Tyr). Tyrosine nitration is the most frequently used and considered the most robust  
7 disease marker of oxidative stress (5–7). Its detection relies mainly on NO<sub>2</sub>Tyr specific  
8 antibodies (8–10). With respect to the nitrogen source, anti-NO<sub>2</sub>Tyr immunopositive signals  
9 are generally interpreted as a hallmark of nitric oxide (NO) being scavenged by superoxide  
10 and intermediate peroxynitrite (9, 11, 12), although other mechanisms exist (13). Regarding  
11 the functional consequences of protein nitration few *in vitro* data exist suggesting mainly  
12 loss of protein function correlating with disease severity (14–17). *In vivo* data are lacking.  
13 Here, we address three major knowledge gaps in our understanding of protein nitration:  
14 specificity, origin, and disease relevance.

## 1 **Results**

2 **Development of an anti-nitrotyrosine antibody panel as biomarkers of disease-**  
3 **relevant oxidative stress.** We started out by examining a panel of anti-NO<sub>2</sub>Tyr antibodies  
4 (**Fig. 1**), including those directed against carrier-linked NO<sub>2</sub>Tyr or against H<sub>2</sub>O<sub>2</sub>/NO<sub>2</sub><sup>-</sup> treated  
5 proteins (see Supplemental Information (**SI Table S1**)). We tested these both in rodent (rat)  
6 and, for later purification, also in porcine tissues. Surprisingly we obtained signals already  
7 under physiological conditions. The immunoreaction, however, varied greatly in protein band  
8 size and intensity. Two polyclonal (pAb), pAb1 and pAb2, and one monoclonal antibody  
9 (mAb), mAb1, displayed the most robust signals (**SI Fig. S1**). The specificity of anti-NO<sub>2</sub>Tyr  
10 antibodies (18–22) is rarely validated, e.g. by antibody pre-absorption with free NO<sub>2</sub>Tyr (11).  
11 In our case, pAb1 signals were partially blocked by pre-absorption with 3 mM NO<sub>2</sub>Tyr. mAb1  
12 showed very little non-specific background whilst pAb2 exhibited moderate sensitivity with  
13 high anti-NO<sub>2</sub>Tyr specificity.

14  
15 **A prominent nitrotyrosine immunoreactive protein band was detected in mouse, rat**  
16 **and pig heart under physiological conditions.** To conduct a tissue/species screen, we  
17 selected three antibodies, pAb1, pAb2, and mAb1, from our original panel (see **SI Table**  
18 **S1**). Three proteins were consistently detected under basal conditions and with apparent  
19 molecular weights of 70, 45 and 38 kDa, of which the latter gave the by far the strongest  
20 signal in heart (**Fig. 2A**). Pre-incubation with free NO<sub>2</sub>Tyr or NO<sub>2</sub>BSA (3 mM) or nitro-group  
21 reduction (21), at least partially, blocked the pAb1 dependent signal. Therefore, subsequent  
22 efforts were directed at identifying the nature of the NO<sub>2</sub>Tyr positive 38 kDa protein and its  
23 site of nitration.

24  
25 **Upon purification, the 38 kDa nitrated protein was identified as LDH with lower V<sub>max</sub>.**  
26 Using porcine heart, we isolated the NO<sub>2</sub>Tyr immunoreactive 38 kDa protein by ion

1 exchange (Q Sepharose, QS) and affinity (Blue Sepharose, BS) chromatography (**Fig. 2B**).  
2 The partially purified 38 kDa protein was stained by colloidal Coomassie Blue and subjected  
3 to peptide mass fingerprinting using MALDI-TOF MS. Based on the NCBIprot database most  
4 ions present in the spectrum of tryptic peptides matched LDH as the primary protein  
5 component of the sample (**Fig. 2C**).

6 Next, we tested the effect of nitration on the enzyme activity by nitrating cardiac LDH  
7 *in vitro* with increasing amounts of  $\text{H}_2\text{O}_2/\text{NO}_2^-$ . Indeed, higher nitration levels of LDH ( $\text{NO}_2$ -  
8 LDH) (**Fig. 2E**) correlated with decreased  $V_{\max}$  (**Fig. 2F**) and unchanged  $K_M$ . Our data  
9 suggest therefore that protein nitration is not only a physiological event for cardiac LDH, but  
10 also modulates enzyme activity by lowering  $V_{\max}$ .

11

12 **Nitrated LDH is increased in diabetes and myocardial stress.** To investigate whether  
13  $\text{NO}_2$ -LDH is further increased in response to metabolic stress, we investigated heart extracts  
14 from rat models of streptozotocin-induced short-term (ST) and long-term (LT) diabetes  
15 mellitus (23) as well as a doxorubicin (DoxoR) induced mouse model of cardiac stress (24)  
16 (**Fig. 3A**). Diabetic rats were sacrificed 3 (ST) and 16 (LT) weeks after inducing diabetes at  
17 week 10. Using the pAb1,  $\text{NO}_2$ -LDH signals were significantly increased in all three models  
18 when compared against healthy controls (**Fig. 3B/C**). Immunosignals of pAb1 pre-absorbed  
19 with  $\text{NO}_2\text{Tyr}$  or anti-LDH wildtype antibody did not show any significant change. In both  
20 diabetes mellitus models and doxorubicin-treatment animals, levels of cardiac LDH were  
21 unchanged versus controls, indicating that indeed the  $\text{NO}_2$ -LDH/LDH ratio was increased.

22

23 **Cardiac LDH nitration is lowered in eNOS-KO and MPO-KO mice.** We next wanted to  
24 address our second goal, to understand the mechanistic origin of the nitrogen in  $\text{NO}_2$ -LDH.  
25 Usually, it is assumed that protein nitration derives from peroxynitrite from the reaction  
26 between  $\cdot\text{NO}$  and  $\text{O}_2\cdot^-$  (25). However, another major source, not involving de novo NO

1 synthesis is frequently overlooked, i.e. MPO-catalyzed nitration using nitrite in the presence  
2 of hydrogen peroxide (26) (**Fig. 4A**). To analyze this *in vivo*, we had to switch to mouse  
3 models, i.e. eNOS-KO and MPO-KO lines. Indeed, we observed that NO<sub>2</sub>-LDH signals in  
4 heart tissue were not only reduced in eNOS-KO but also in MPO-KO mice when compared  
5 to their respective WT litter mates (**Fig. 4B**). These results therefore indicated that both  
6 pathways contribute to basal nitration of cardiac LDH.

7  
8 **Further MALDI-TOF mass spectrometry analysis of the nitration site identifies the**  
9 **nitrate residue as tryptophan and not tyrosine.** A similarly frequent assumption about  
10 NO<sub>2</sub>Tyr immunosignals is specificity with respect to the nitrated amino acid. Other nitration  
11 target amino acids, however, have been reported, most prominently tryptophan (27–29). To  
12 identify the physiologically nitrated LDH residue(s), heart tissue was homogenized and  
13 subjected to 2D-PAGE in-gel digestion prior to MALDI-TOF MS analysis. Surprisingly,  
14 signals consistent with a nitrated tryptophan at position 324 of peptide 319-328  
15 (SADTLWGIQK) of LDH (NO<sub>2</sub>Trp-LDH) were detected (**Fig. 5A**). We cannot exclude  
16 nitration of other peptides of LDH that were below our level of detection. Nevertheless, our  
17 results strongly point to NO<sub>2</sub>Trp being detected by the supposedly anti-NO<sub>2</sub>Tyr pAb1.

18  
19 **NO<sub>2</sub>Trp-LDH molecular dynamics simulations suggested higher restriction of the**  
20 **activity-essential interaction of the active site loop with the C-terminal  $\alpha$ -helix.** Since  
21 we did observe a  $V_{max}$  effect on NO<sub>2</sub>-LDH, we wanted to investigate whether there is a likely  
22 structural correlate for this via Trp-324. We therefore modeled the nitration into the structure  
23 of tetrameric and binary human LDH, and then performed molecular dynamics simulations.  
24 For distance metrics of human LDH and key structural components refer to **Fig. 5B**. The  
25 root-mean squared fluctuations (RMSF) of all atoms in each residue were averaged across  
26 the four subunits in each combined 3.5  $\mu$ s trajectory (**SI Fig. S2**). Subtracting the wildtype



1 tetramer (WT) RMSF from the T4N (tetramer with NO<sub>2</sub>Trp-324 residue on each subunit)  
2 highlighted differences in mobility between the dynamics of the WT compared with NO<sub>2</sub>Trp-  
3 LDH (**Fig. 5C**). Positive values in the resulting graphs indicated greater mobility of residues  
4 in T4N compared with WT and *vice versa*. Moreover, distance histograms (**Fig 5D/E**) show  
5 an increased mobility in the binary complexes compared with the ternary, expressed as a  
6 broadening of the histograms.

7         We found that NO<sub>2</sub>Trp-LDH weakened the interaction between  $\alpha$ -H and the active  
8 site loop. This decoupling led to a greater population of closed and “over-closed” states of  
9 the T4N active-site loop. By corollary, in WT LDH, the open active-site loop states are partly  
10 stabilized by interaction with the  $\alpha$ -H helix. Therefore, nitration of LDH is expected to  
11 decrease LDH activity, consistent with our enzyme-kinetic findings (see **Fig. 2D-E**).

## 1 Discussion

2 We here close three major knowledge gaps in our understanding of protein nitration:  
3 specificity, origin, and disease relevance. With respect to the specificity of protein nitration,  
4 a vast heterogeneity of proteins are detected by supposedly uniform anti-NO<sub>2</sub>Tyr antibodies.  
5 Moreover, tryptophan nitration (NO<sub>2</sub>Trp) was a cofounding factor of our apparent NO<sub>2</sub>Tyr-  
6 immunosignals. Protein NO<sub>2</sub>Trp formation has been described in isolated proteins treated  
7 with H<sub>2</sub>O<sub>2</sub>/NO<sub>2</sub><sup>-</sup> *in vitro* (30–33), peroxynitrite-exposed cells (34), and as physiological  
8 modification during aging in rat heart mitochondria (28). Trp is an alternative target of  
9 nitration that deserves more attention (35, 36) and immunosignals by anti-NO<sub>2</sub>Tyr antibodies  
10 should rather be interpreted as NO<sub>2</sub>Tyr/ NO<sub>2</sub>Trp signals unless purified and chemically  
11 validated. Rebrin et al. (28) reported Trp nitration of succinyl-CoA:3-ketoacid CoA  
12 transferase (SCOT), which could not be reproduced by Wang et al. (37). Whether Trp  
13 nitration has a functional consequence on SCOT remained unclear because both activation  
14 and inactivation were observed (28). In hindsight, SCOT nitration is also the first  
15 documented example where Trp nitration has been mistaken as Tyr nitration based on  
16 cross-reactivity of a supposedly NO<sub>2</sub>Tyr specific antibody (38), and many more of these  
17 examples may exist in the literature.

18 With respect to the origin of the nitrating nitrogen in NO<sub>2</sub>Tyr/ NO<sub>2</sub>Trp positive proteins,  
19 we show that both eNOS/NO and MPO/nitrite pathways, and possibly others, need to be  
20 equally considered and that the *a priori* assumption that NO<sub>2</sub>Tyr immunosignals indicate NO  
21 scavenging by superoxide is not valid.

22 With respect to disease relevance, probably our most relevant finding is that protein  
23 nitration is a physiological event. This represents a similar dogma shift as for ROS formation,  
24 which also should not be *a priori* considered as oxidative stress and a disease marker. Thus,  
25 both ROS and reactive nitrogen and protein nitration represent physiological events, even  
26 though they may be upregulated in disease as we show for diabetes and cardiac stress.

1 Not many specific functional consequences have been described for protein nitration.  
2 Assuming Trp nitration and activity modulation of both LDH (decreasing activity) and SCOT  
3 (increasing activity) would occur, this may be a protective mechanism, allowing the heart to  
4 better utilize ketone metabolism for energy production at a time when other metabolic  
5 processes may be diminished (27, 28). Molecular dynamics simulations were performed on  
6 NO<sub>2</sub>-LDH, aiming to understand the impairment of the enzyme activity (see **Fig. 5**). While  
7 differences in activity between WT and T4N of a factor of two is significant in physiological  
8 terms, it corresponds to minor changes in the free energy states in the catalytic process.  
9 The catalytic cycle of LDH is a well understood ordered bi-bi reaction mechanism where  
10 substrate and product enter and leave the active-site, with concomitant closing and opening  
11 of the active-site loop, after cofactor binding. Detailed kinetic characterization of LDH from  
12 *Bacillus stearothermophilus* (39) and *Plasmodium falciparum* (40) has revealed this loop  
13 movement to be a rate limiting step in the reaction mechanism. Any perturbation of this  
14 delicately balanced conformational change is expected to compromise the catalytic activity  
15 of the enzyme. We suggest that conformational movement of the active-site loop in cardiac  
16 LDH is also a rate limiting step and the weakening of the interaction between this loop and  
17 the  $\alpha$ -H helix in T4N (as described in our results) is responsible for the impaired catalytic  
18 activity.

19 In conclusion, cardiac LDH appears to be the first protein basally regulated by  
20 nitration and not only a loss-of-function biomarker of metabolic stress. NO<sub>2</sub>-LDH has a lower  
21  $V_{max}$  and the nitration is further increased under cardiac metabolic stress. Furthermore, *in*  
22 *vivo* NO<sub>2</sub>Tyr immunoreactivity not necessarily reflects Tyr nitration or solely NO scavenging.  
23 Instead, it may indicate nitrite/MPO-dependent Trp nitration and physiological signaling. This  
24 has wide implications on re-interpreting previous data using NO<sub>2</sub>Tyr immunoreactivity as a  
25 biomarker and on our understanding of nitration as a physiological protein modification and  
26 signaling mechanism.

## 1 **Material and Methods**

2 Detailed experimental procedures are provided in *SI Materials and Methods*.

1 **Footnotes**

2

3 **Footnote 1.** Several publications on protein NO<sub>2</sub>Tyr immunoreactions report the use of  
4 NO<sub>2</sub>Tyr concentrations of up to 10 mM to block the signal and demonstrate specificity; this  
5 exceeds the solubility of NO<sub>2</sub>Tyr. Moreover, these saturated solutions are highly acidic and  
6 require buffering to ensure that any blockade of an immunosignal is due to competition with  
7 free NO<sub>2</sub>Tyr and not due to pH-induced antibody denaturation.

8

9 Author contributions: H.H.H.W.S. designed research; J.F., D.T., T.N., C.I.A., A.S., P.B.,  
10 C.S., V.S., P.R., A.J., A.G., D.H.P., R.B.S. and M.F. performed research; A.S., A.G., A.K.,  
11 S.B., D.H.P., M.F. and H.H.H.W.S. contributed new reagents/analytic tools; J.F., D.T.,  
12 D.H.P., and H.H.H.W.S. analyzed data; and C.N., J.F., C.S., D.H.P., M.F., A.I.C. and  
13 H.H.H.W.S. wrote the paper.

14

15 The authors declare no conflict of interests.

16 This article is a PNAS regular research article.

17 This article contains supplemental information (SI Appendix).

## 1 **Acknowledgements**

2 Work in A.J. laboratory was supported by BBSRC, BHF and MRC; in P.B. laboratory by  
3 NKFIH (K123975); in H.H.H.W.S. laboratory by an ERC Advanced Investigator Grant  
4 (294683 - RadMed), an ERC proof-of-concept grant (139-101052 - SAVEBRAIN) and the  
5 EU Horizon 2020 programme, REPO-TRIAL. The authors would like to thank G. Jansen for  
6 technical help, and Dr. P.M.H. Schiffers for carefully reading earlier stages of the manuscript.  
7 We also thank the Advanced Computing Research Centre at Bristol and BrisSynBio for  
8 access to the HPC machines BlueCrystal and BlueGem. We thank the HECBiosim  
9 Consortium for access to the UK National HPC facility Archer.

## 1 **References**

- 2 1. Sies H (2015) Oxidative stress: a concept in redox biology and medicine. *Redox Biol*  
3 4:180–183.
- 4 2. Beckman JS, Koppenol WH (1996) Nitric oxide, superoxide, and peroxynitrite: the  
5 good, the bad, and ugly. *Am J Physiol Physiol* 271(5 Pt 1):C1424-37.
- 6 3. Radi R (2004) Nitric oxide, oxidants, and protein tyrosine nitration. *Proc Natl Acad*  
7 *Sci* 101(12):4003–4008.
- 8 4. Armitage ME, Wingler K, Schmidt HHHW, La M (2009) Translating the oxidative  
9 stress hypothesis into the clinic: NOX versus NOS. *J Mol Med* 87(11):1071–1076.
- 10 5. Viappiani S, Schulz R (2006) Detection of specific nitrotyrosine-modified proteins as  
11 a marker of oxidative stress in cardiovascular disease. *AJP Hear Circ Physiol*  
12 290(6):H2167–H2168.
- 13 6. Shishehbor MH, Hazen SL (2004) Inflammatory and oxidative markers in  
14 atherosclerosis: Relationship to outcome. *Curr Atheroscler Rep* 6(3):243–50.
- 15 7. Ho E, Karimi Galoughi K, Liu C-C, Bhindi R, Figtree GA (2013) Biological markers  
16 of oxidative stress: Applications to cardiovascular research and practice. *Redox Biol*  
17 1(1):483–491.
- 18 8. Fernández E, García-Moreno J-M, Martín de Pablos A, Chacón J (2013) May the  
19 Evaluation of Nitrosative Stress Through Selective Increase of 3-Nitrotyrosine  
20 Proteins Other Than Nitroalbumin and Dominant Tyrosine-125/136 Nitrosylation of  
21 Serum  $\alpha$ -Synuclein Serve for Diagnosis of Sporadic Parkinson's Disease? *Antioxid*  
22 *Redox Signal* 19(9):912–918.
- 23 9. Halliwell B (1997) What nitrates tyrosine? Is nitrotyrosine specific as a biomarker of  
24 peroxynitrite formation in vivo? *FEBS Lett* 411(2–3):157–160.
- 25 10. Ye YZ, Strong M, Huang Z-QQ, Beckman JS (1996) Antibodies that recognize  
26 nitrotyrosine. *Methods Enzymol* 269:201–209.

- 1 11. Reiter CD, Teng R-J, Beckman JS (2000) Superoxide Reacts with Nitric Oxide to  
2 Nitrate Tyrosine at Physiological pH via Peroxynitrite. *J Biol Chem* 275(42):32460–  
3 32466.
- 4 12. Breusing N, Grune T (2010) Biomarkers of protein oxidation from a chemical,  
5 biological and medical point of view. *Exp Gerontol*. doi:10.1016/j.exger.2010.04.004.
- 6 13. Sampson JB, Ye Y, Rosen H, Beckman JS (1998) Myeloperoxidase and  
7 Horseradish Peroxidase Catalyze Tyrosine Nitration in Proteins from Nitrite and  
8 Hydrogen Peroxide. *Arch Biochem Biophys* 356(2):207–213.
- 9 14. Bigelow DJ (2009) Nitrotyrosine-modified SERCA2: a cellular sensor of reactive  
10 nitrogen species. *Pflügers Arch - Eur J Physiol* 457(3):701–710.
- 11 15. Knyushko T V., Sharov VS, Williams TD, Schöneich C, Bigelow DJ (2005) 3-  
12 Nitrotyrosine Modification of SERCA2a in the Aging Heart: A Distinct Signature of  
13 the Cellular Redox Environment †. *Biochemistry* 44(39):13071–13081.
- 14 16. Li H, Gutterman DD, Rusch NJ, Bubolz A, Liu Y (2004) Nitration and Functional Loss  
15 of Voltage-Gated K<sup>+</sup> Channels in Rat Coronary Microvessels Exposed to High  
16 Glucose. *Diabetes* 53(9):2436–2442.
- 17 17. Haddad IY, Zhu S, Ischiropoulos H, Matalon S (1996) Nitration of surfactant protein  
18 A results in decreased ability to aggregate lipids. *Am J Physiol Cell Mol Physiol*  
19 270(2):L281-8.
- 20 18. Akaike T, et al. (1996) Pathogenesis of influenza virus-induced pneumonia:  
21 involvement of both nitric oxide and oxygen radicals. *Proc Natl Acad Sci* 93(6):2448–  
22 2453.
- 23 19. Akaike T, et al. (2003) 8-Nitroguanosine formation in viral pneumonia and its  
24 implication for pathogenesis. *Proc Natl Acad Sci* 100(2):685–690.
- 25 20. Evans TJ, et al. (1996) Cytokine-treated human neutrophils contain inducible nitric  
26 oxide synthase that produces nitration of ingested bacteria. *Proc Natl Acad Sci*



- 1 93(18):9553–9558.
- 2 21. Hayashi T, et al. (2006) Modulating role of estradiol on arginase II expression in  
3 hyperlipidemic rabbits as an atheroprotective mechanism. *Proc Natl Acad Sci*  
4 103(27):10485–10490.
- 5 22. Szabo C, et al. (1998) Protection against peroxynitrite-induced fibroblast injury and  
6 arthritis development by inhibition of poly(ADP-ribose) synthase. *Proc Natl Acad Sci*  
7 95(7):3867–3872.
- 8 23. Graham ML, Janecek JL, Kittredge JA, Hering BJ, Schuurman HJ (2011) The  
9 streptozotocin-induced diabetic nude mouse model: Differences between animals  
10 from different sources. *Comp Med*. doi:10.1152/ajprenal.00292.2015.
- 11 24. Berthiaume JM, Wallace KB (2007) Adriamycin-induced oxidative mitochondrial  
12 cardiotoxicity. *Cell Biology and Toxicology* doi:10.1007/s10565-006-0140-y.
- 13 25. Peluffo G, Radi R (2007) Biochemistry of protein tyrosine nitration in cardiovascular  
14 pathology. *Cardiovasc Res* 75(2):291–302.
- 15 26. van der Vliet A, Eiserich JP, Halliwell B, Cross CE (1997) Formation of Reactive  
16 Nitrogen Species during Peroxidase-catalyzed Oxidation of Nitrite. *J Biol Chem*  
17 272(12):7617–7625.
- 18 27. Nuriel T, Hansler A, Gross SS (2011) Protein nitrotryptophan: Formation,  
19 significance and identification. *J Proteomics* 74(11):2300–2312.
- 20 28. Rebrin I, Brégère C, Kamzalov S, Gallaher TK, Sohal RS (2007) Nitration of  
21 Tryptophan 372 in Succinyl-CoA:3-Ketoacid CoA Transferase during Aging in Rat  
22 Heart Mitochondria †. *Biochemistry* 46(35):10130–10144.
- 23 29. Souza JM, Peluffo G, Radi R (2008) Protein tyrosine nitration—Functional alteration  
24 or just a biomarker? *Free Radic Biol Med* 45(4):357–366.
- 25 30. Suzuki T, et al. (2004) Nitration and nitrosation of N-acetyl-L-tryptophan and  
26 tryptophan residues in proteins by various reactive nitrogen species. *Free Radic Biol*


- 1            *Med* 37(5):671–681.
- 2 31. Yamakura F, Ikeda K (2006) Modification of tryptophan and tryptophan residues in  
3 proteins by reactive nitrogen species. *Nitric Oxide* 14(2):152–161.
- 4 32. Yamakura F, et al. (2005) Nitrated and Oxidized Products of a Single Tryptophan  
5 Residue in Human Cu,Zn-Superoxide Dismutase Treated with Either Peroxynitrite-  
6 Carbon Dioxide or Myeloperoxidase-Hydrogen Peroxide-Nitrite. *J Biochem*  
7 138(1):57–69.
- 8 33. Yamakura F, Matsumoto T, Taka H, Fujimura T, Murayama K (2003) 6-  
9 Nitrotryptophan: a specific reaction product of tryptophan residue in human Cu, Zn-  
10 SOD treated with peroxynitrite. *Adv Exp Med Biol* 527:745–9.
- 11 34. Ikeda K, et al. (2007) Detection of 6-nitrotryptophan in proteins by Western blot  
12 analysis and its application for peroxynitrite-treated PC12 cells. *Nitric Oxide*  
13 16(1):18–28.
- 14 35. Alvarez B, et al. (1996) Peroxynitrite-Dependent Tryptophan Nitration. *Chem Res*  
15 *Toxicol* 9(2):390–396.
- 16 36. Herold S (2004) Nitrotyrosine, dityrosine, and nitrotryptophan formation from  
17 metmyoglobin, hydrogen peroxide, and nitrite. *Free Radic Biol Med* 36(5):565–579.
- 18 37. Wang Y, et al. (2010) The Nitrated Proteome in Heart Mitochondria of the db/db  
19 Mouse Model: Characterization of Nitrated Tyrosine Residues in SCOT. *J Proteome*  
20 *Res* 9(8):4254–4263.
- 21 38. Marcondes S, Turko I V, Murad F (2001) Nitration of succinyl-CoA:3-oxoacid CoA-  
22 transferase in rats after endotoxin administration. *Proc Natl Acad Sci* 98(13):7146–  
23 7151.
- 24 39. Wilks HM, et al. (1990) Designs for a broad substrate specificity keto acid  
25 dehydrogenase. *Biochemistry* 29(37):8587–8591.
- 26 40. Shoemark DK, Cliff MJ, Sessions RB, Clarke AR (2007) Enzymatic properties of the

- 1 lactate dehydrogenase enzyme from *Plasmodium falciparum*. *FEBS J*  
2 274(11):2738–2748.
- 3 41. Viera L, Ye YZ, Estévez AG, Beckman JS (1999) [39] Immunohistochemical  
4 methods to detect nitrotyrosine. *Methods in Enzymology*, pp 373–381.
- 5 42. Görg A, Weiss W, Dunn MJ (2004) Current two-dimensional electrophoresis  
6 technology for proteomics. *Proteomics* 4(12):3665–3685.
- 7 43. Perlman DH, Berg EA, O'Connor PB, Costello CE, Hu J (2005) Reverse  
8 transcription-associated dephosphorylation of hepadnavirus nucleocapsids. *Proc*  
9 *Natl Acad Sci* 102(25):9020–9025.
- 10 44. Karas M, Hillenkamp F (1988) Laser desorption ionization of proteins with molecular  
11 masses exceeding 10,000 daltons. *Anal Chem* 60(20):2299–2301.
- 12 45. Sousa da Silva AW, Vranken WF (2012) ACPYPE - AnteChamber PYthon Parser  
13 interface. *BMC Res Notes* 5(1):367.
- 14 46. Lindorff-Larsen K, et al. (2010) Improved side-chain torsion potentials for the Amber  
15 ff99SB protein force field. *Proteins Struct Funct Bioinforma* 78(8):NA-NA.
- 16 47. Abraham MJ, et al. (2015) GROMACS: High performance molecular simulations  
17 through multi-level parallelism from laptops to supercomputers. *SoftwareX* 1–2:19–  
18 25.
- 19 48. Humphrey W, Dalke A, Schulten K (1996) VMD: Visual molecular dynamics. *J Mol*  
20 *Graph* 14(1):33–38.
- 21 49. Pettersen EF, et al. (2004) UCSF Chimera?A visualization system for exploratory  
22 research and analysis. *J Comput Chem* 25(13):1605–1612.
- 23 50. Pacher P (2003) Potent Metalloporphyrin Peroxynitrite Decomposition Catalyst  
24 Protects Against the Development of Doxorubicin-Induced Cardiac Dysfunction.  
25 *Circulation* 107(6):896–904.
- 26 51. Perlman DH, et al. (2009) Mechanistic Insights Into Nitrite-Induced Cardioprotection

1 Using an Integrated Metabolomic/Proteomic Approach. *Circ Res* 104(6):796–804.

2

## 1 Figures and figure legends




2

### 3 **Figure 1. Experimental outline for an anti-NO<sub>2</sub>Tyr antibody-based biomarker detection**


4 **approach.** Central panel: Antibody panel screening, an anti-NO<sub>2</sub>Tyr antibody panel was  
5 tested in porcine and rat tissues under physiological conditions. Different antibodies might  
6 recognize different nitrated proteins (green and orange antibodies) or one antibody might  
7 detect more than one nitrated protein (blue antibody). Right panel: A 38 kDa band was  
8 especially prominent and, subsequently, purified in large mammals and identified via  
9 MALDI-TOF as LDH. NO<sub>2</sub>-LDH activity was also assessed. We identified the nitrated residue  
10 and simulated the effect of the nitration in the protein structure and mechanism using human  
11 LDH. Left panel: Different rodent models, as well as knock-out mouse models were used to  
12 elucidate the effects of NO<sub>2</sub>-LDH in disease, diabetes and myocardial stress, and the  
13 enzymatic sources of reactive nitrogen species (RNS) leading to LDH nitration, respectively.

14



1 **Figure 2. Screening of different native tissue homogenates identifies a 38 kDa band**  
 2 **in heart as major physiologically NO<sub>2</sub>Tyr-immunopositive protein. Further**  
 3 **purification and MALDI-MS analysis identified the 38 kDa band as LDH. (A)**  
 4 **Immunopositive pig and rat tissues from Fig S1 were further analyzed by SDS-PAGE under**  
 5 **reducing conditions (dithiothreitol) and subsequent western blot. The band pattern was**  
 6 **different for all three polyclonal (pAb) or monoclonal (mAb) antibodies: pAb1, mAb1 and**  
 7 **pAb2. The most intense NO<sub>2</sub>Tyr immunopositive protein band at approximately 38 kDa**  
 8 **(p38<sup>nt</sup>) was detected using pAb1 in heart. (B) p38<sup>nt</sup> was purified from porcine heart**  
 9 **homogenate by affinity (Blue Sepharose) followed by ion-exchange (Q-Sepharose)**  
 10 **chromatography. Purification steps were tracked via protein nitrotyrosine detection using**  
 11 **pAb1. (C) Purified cardiac p38<sup>nt</sup> was cut out from the gel, digested with trypsin and analyzed**

1 by mass spectrometry and peptide mass fingerprint analysis. Most peptide ions detected  
2 were matched to lactate dehydrogenase: 11 ions matched to LDH (■) out of a total of 20  
3 detected, with 5 ions matching to the next best protein assignment, malate dehydrogenase  
4 (MDH, □), identifying p38<sup>nt</sup> as LDH with a  $p < 0.05$ . (D) LDH nitration was assessed by  
5 quantitative western blot analysis using pAb1 (n=9). (E)  $V_{\max}$ [LDH] remained unchanged  
6 up to an equimolar peroxynitrite:LDH ratio, and then decreased at a ratio of 10 (n=8). Data  
7 represent means  $\pm$ SEM.



1

2 **Figure 3. Pathological LDH nitration levels in short-term (ST) and long-term (LT)**

3 **diabetic disease models and an oxidative stress myocardial dysfunction model. (A)**

4 Heart homogenates of ST and LT streptozotocin-treated diabetic rats or doxorubicin-treated

5 mice (DoxoR) were analyzed by SDS-PAGE and immunoblot analysis for LDH nitration

6 using the pAb1 antibody. (B) In all three animal models, the relative NO<sub>2</sub>-LDH signal intensity

7 was increased. In diabetes, the long-term model yielded higher values than the short-term

8 model, which may indicate either higher nitrosative stress, or, more likely, accumulation of


9 LDH nitration. The highest increase was observed in the doxorubicin model. Data are

10 expressed as % of untreated control animals (open bars) and represent means ± SEM of

11 n=6-18 experiments.

12





1

2 **Figure 4. *In vivo* genetic validation of reactive nitrogen species (RNS) sources. (A)**

3 Events leading to oxidized and nitrated LDH. RNS (represented as NO<sub>2</sub><sup>-</sup>/H<sub>2</sub>O<sub>2</sub>/ONOO<sup>-</sup>) can

4 nitrate LDH, resulting in decreased V<sub>max</sub>. (B) Cardiac tissue was obtained from endothelial

5 nitric oxide synthase (eNOS) and myeloperoxidase (MPO) knock-out (KO), and the


6 respective wild-type (WT), mice. Basal nitration of LDH (p38<sup>nt</sup>) was analyzed by immunoblot,

7 and immunosignals quantified densitometrically. Data are expressed as % of control (i.e., of


8 the respective WT animals) and represent means ± SEM of n=3-5 animals. NO<sub>2</sub>-LDH

9 depended on both eNOS and MPO.


10

**A****NO<sub>2</sub>-LDH MALDI-TOF MS-based residue identification****B**


Protein structure  
WT human LDH

**C**


WT and T4N backbone RMSF differences per residue

**D**

Association of the active site with α-H (m:LH)


**E**

Openness of the active site loop (m:LO)



1 **Figure 5. Identification of LDH Trp-324 as physiologically nitrated and oxidized. The**  
2 **interaction of the active site loop with the C-terminal  $\alpha$ -helix is essential and restricted**  
3 **in  $\text{NO}_2$ Trp-LDH.** (A) Rat heart homogenate was subjected to 2D-PAGE and Coomassie  
4 staining; spots were subjected to in-gel digestion and MALDI-TOF MS analysis. Left panel:  
5 Mass spectrum derived from a spot corresponding to rat LDH over the range m/z 600 to  
6 2700. Right panel: An expansion of the same spectrum over the range m/z 1170 to 1230,  
7 showing peptide ions assigned primarily to the peptide 319-328 (319SADTLWDIQK328),  
8 and its oxidized and nitrated derivatives. Major peptide ions are labeled with their observed  
9 m/z values and corresponding LDH mature protein amino acid intervals, as assigned by  
10 Mascot™, and additionally by manual comparison to predicted values calculated from the  
11 LDH sequence and oxidative and nitrative modifications. The ions correspond to the peptide  
12 319-328 Trp (W)-nitrated species (319-328 +  $\text{NO}_2$ ) and its typical high energy  
13 decomposition product (319-328 +  $\text{NO}_2\text{-O}$ ), as well as ions corresponding to the  
14 characteristic family of Trp oxidation forms, hydroxytryptophan (319-328 + Ox), didehydro-  
15 hydroxytryptophan (319-328 + Ox-2H), dihydroxytryptophan (319-328 + 2Ox), and  
16 kynurenin (319-328 + Ox-C). Other peptide ions display single (+ Ox) and double (+ 2Ox)  
17 oxidation, or didehydrogenation (- 2H). (B) Distance metrics mapped onto the crystal  
18 structure of WT (1I0Z). Color scheme:  $\beta$ -K-- $\beta$ -K loop, dark blue;  $\alpha$ -helix, pink; active-site  
19 loop, green;  $\alpha$ -2G, light blue; pyruvate, grey; NADH, cyan. Residue Trp-324 is shown in  
20 space filling. (C) Plot of the differences between T4N and WT backbone RMSF per residue  
21 (T4N – WT) in the binary complex. Structures are highlighted using the same color scheme  
22 as previously described plus the juxtaposed loop to the C-terminal  $\alpha$ -helix which is  
23 highlighted in light orange. (D – E) Histograms of the distribution of distances. Blue WT; Red  
24 T4N. Metrics m:LH (107:CB-326:CB) showing the juxtaposition of the active-site loop and  
25  $\alpha$ -C-terminal helix and m:LO (103:CA-243:CB) showing the open/closed state of the active-  
26 site loop.

# anti-NO<sub>2</sub>Tyr antibody based biomarker detection




Mouse

Rat

Pig

Human




**A****Disease specificity**

Rat



Diabetes



Short-term

Long-term





Mouse



+

Doxorubicin




Cardiotoxicity

**B**NO<sub>2</sub>-LDH Immunosignal [% of control]**C**NO<sub>2</sub>-LDH Immunosignal [% of control]


**A****Enzymatic sources of RNS****B**

NO<sub>2</sub>-LDH MALDI-TOF MS-based residue identification




**B**

Protein structure  
WT human LDH




**C**

WT and T4N backbone RMSF differences per residue




**D**

Association of the active site with α-H (m:LH)



**E**

Openness of the active site loop (m:LO)





Antigen \ Antibody	pAb1 1:3000	pAb2 1:3000	mAb1 1:3000
NO <sub>2</sub> Tyr-Block	+	+	+
NO <sub>2</sub> BSA (Control)			
Pul. Artery (pig)			
Heart (pig)			
Lung (rat)			
Kidney (rat)			
Cerebellum (rat)			
Spleen (rat)			
Cortex (rat)			

